Background: This study aimed to evaluate renal function before, during, and after the
| INTRODUCTION
Tuberculosis (TB) is a public health problem and 80% of cases occur in developing countries. 1, 2 The incidence in Brazil is 30.9 cases/100 000 inhabitants, with about 70 000 new cases per year and 4.4 thousand deaths. 3 TB is the most common neglected tropical disease occurring after kidney transplantation. 4 It occurs by either activation of quiescent foci of Mycobacterium tuberculosis, transmission via the allograft, or new acquisition from exposure to another person with the infection. The incidence of TB in transplant recipients is 20-50 times higher than in the general population, ranging from 0.5% to 1% in North America to 15% in India and Pakistan. 4 Studies in Brazilian transplant centers have reported incidences of 1.17% to 5%.
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Previous studies have shown that TB in kidney transplant recipients (KTRs) predominantly occurs as extrapulmonary or disseminated forms and is associated with high mortality. 4 In addition, some studies have reported high rates of death-censored graft loss in the months following the TB diagnosis. Acute rejection (AR) and chronic rejection secondary to immunosuppressive minimization or withdrawal because of disease severity are the main reported causes of graft loss. 5, 9, 10 Little is known about the impact of TB disease and its treatment on renal allograft function. To the best of our knowledge, no study has systematically evaluated renal function during and after TB disease in KTRs.
The aim of this single-center retrospective study was to evaluate the incidence of acute kidney injury (AKI) during TB disease in a cohort of KTRs living in an endemic region, to assess renal function 3 months after the treatment, and evaluate the risk factors for non-recovery of baseline renal function.
| MATERIALS AND METHODS
Retrospective cohort study including patients who received a kidney allograft between January 1994 and November 2014 in a single center in Fortaleza, Ceará, located in the Northeast of Brazil, and had TB disease after transplantation. The study was approved by the local Ethics Committee.
Patients who received multiorgan transplants, those who were lost to follow-up within the first 6 months after transplantation, and patients with insufficient clinical data were excluded. All patients treated
for TB for at least 6 months or until death were included. In the study period, TB diagnosis was based on positive acid-fast bacilli (AFB) smear, high adenosine deaminase levels, histological findings, and positive culture for M. tuberculosis. Empirically treated patients were also included when clinical presentation was suggestive, extensive clinical investigation excluded other diagnoses, and clinical improvement was observed after treatment. These cases were defined as "presumed TB."
According to local practice, patients with prior TB at any time before transplantation, patients with tuberculin skin test (TST) reaction ≥5 mm, or patients who had contact with active TB received treatment for latent TB infection (LTBI), with isoniazid 300 mg/day for 6 months. 11 To improve adherence, patient education and instructions were provided at every visit and compliance to treatment was monitored using patients' self-reports. Non-recovery of baseline renal function was defined as graft loss or
Cr post at least 25% higher than Cr base . 
| Statistical analysis

| RESULTS
| Population and demographics
Of 1604 patients submitted to kidney transplantation during the study period, 34 (2.1%) were diagnosed with post-transplant TB.
Patients were predominantly young (41.0±12.7 years), male (70.6%), non-Caucasian (76.5%), and were submitted to deceased-donor transplantations (58.8%). Induction therapy with depleting or nondepleting antibodies was used in 61.8%. The TB diagnosis was attained 25.5 (1-168) months after the transplantation and 30 patients (88.2%) were receiving calcineurin inhibitor-based regimens. Fifteen (44.1%) patients had AR episodes 10.5 (1-196) months before the TB diagnosis (Table 1) .
Of the 34 patients, 1 received LTBI therapy because of TB disease that occurred 14 years prior to kidney transplantation; 21 patients had no clinical indication for isoniazid; 10 received isoniazid because of the TST ≥5 mm; and 2 patients had indication for LTBI treatment because of TST ≥5 mm, but accidentally they did not receive it ( Figure 1 ). Of the 10 patients who developed TB disease despite LTBI treatment, in 3 patients the disease occurred early after transplantation (2, 3, and 4 months), still during isoniazid therapy. Two of these three had the disseminated forms, including in the urinary tract. In the remaining seven patients, TB disease occurred after isoniazid therapy, late after transplantation (mean of 38 months, ranging from 8 to 90 months). In a single patient, close contact with a relative who had active pulmonary TB was documented and a new exposure was considered likely.
There were no reports of non-compliance to LTBI treatment in the medical records.
| Clinical presentation, diagnosis, and treatment
The main symptoms were fever (76.5%), weight loss (58.8%), and cough (44.1%). Fifteen patients (44.1%) had isolated pulmonary involvement; 13 (38.2%) had one extrapulmonary site; 1 (2.9%) had pleuropulmonary TB; 4 (11.8%) had disseminated TB; and 1 patient who had prolonged fever of unknown origin were empirically treated for TB. (presumed TB): two presented with fever and pulmonary infiltrates.
They had negative bronchoalveolar lavage smears and cultures and no alternative diagnosis on available serological and molecular testing.
After empirical treatment, they showed fever resolution and improvement in pulmonary infiltrates. One patient had fever of unknown origin and weight loss. Extensive clinical investigation was performed and no cause was found. After treatment, there was clinical improvement and fever resolution. For detailed information about clinical presentation and diagnosis, see Table 2 .
For all patients, TB treatment was a combination of three or four antituberculous drugs for 12.2±6.9 months (range 3-36 months).
Eleven patients (32. Clinical management after TB diagnosis, including immunosuppressive drug monitoring, was performed at the discretion of the attending physician.
| Renal function and outcomes
The mean serum Cr at baseline (Cr base ) was 1. Although low exposure to tacrolimus occurred after TB treatment, the concentration was adequate at the time of graft dysfunction. There was no unequivocal evidence of non-compliance. He received methylprednisolone and Cr levels decreased.
After the onset of TB treatment, mean tacrolimus trough levels decreased from 6.2±2.3 ng/mL (before treatment) to 1.9±1.0 ng/mL (first concentration after treatment), reaching 1.7±0.8 ng/mL (the lowest value). Similar underexposure occurred with cyclosporine, for which C2 levels were reduced from 619±213 to 408±161 ng/mL, reaching 295±149 ng/mL. Significant variability was seen in the intervals be- (Table 3) .
We also compared the five patients who lost their grafts with the 29 who persisted with functioning grafts. As a result, the mean 
| DISCUSSION
This study showed that TB disease is associated with a significant incidence of AKI and permanent allograft impairment. Severe AKI and AR episodes, which are common events during TB disease, are possible risk factors for non-recovery of baseline allograft function.
In our cohort of KTRs, the demographics and clinical characteristics of TB disease were quite similar to those described by other F I G U R E 1 Distribution of patients with tuberculosis (TB) disease after kidney transplantation according to latent TB screening. TST, tuberculin skin test; LTBI, latent TB infection. LTBI therapy was performed using isoniazid 300 mg/day for 6 months transplant centers located in endemic regions, with late occurrence, high incidence of extrapulmonary and disseminated forms, difficulty in attaining a definitive diagnosis, and prolonged treatments. were not identified by the available methods. Early TB disease after transplantation in patients with or without isoniazid treatment, may even be due to unrecognized active disease at the time of transplantation or donor-derived infection. Compared with Brazilian studies, TB incidence was somewhat lower. [5] [6] [7] [8] It is possible that the routine use of LTBI therapy for at-risk patients might be the reason for this finding.
Our data showed a significant increase in serum Cr during and after TB diagnosis and, consequently, a high prevalence of AKI, including the severe forms. Graft dysfunction has been previously described in other TB cohorts, but little has been reported about the causes of AKI. 6, 8 In our study, prerenal azotemia, sepsis, AR, and drug nephrotoxicity were the main identified causes of graft dysfunction.
The pharmacokinetics interaction between the antituberculous drugs, especially rifampicin, and calcineurin inhibitors is an important cause of the increased incidence of AR during TB treatment. Furthermore, in clinically severe patients, the staff often minimizes maintenance immunosuppression, which is also a risk factor for immune-mediated events.
Three months after TB treatment, when adjusting GFR for deaths and graft losses, patients did not recover the baseline renal function, showing a permanent damage to the allograft function and structure. Interestingly, the TB disease and AKI severity, and AR episodes were associated with this outcome. These variables were not significant in the multivariable analysis, probably owing to the small sample size.
This study has the limitations inherent to a retrospective and single-center study. These results reflect the clinical presentation of TB disease in patients living in a country with endemic TB, and may not be extrapolated to low-incidence areas. Although treated as having TB, not all patients had this diagnosis confirmed. Considering the severity of TB in KTRs and the endemicity in our country, empirical treatment is a relatively common practice in patients with high clinical suspicion and logistical difficulties for an extensive investigation.
Moreover, in developing countries, even though cultures are more sensitive than microscopy analysis, diagnosis is primarily based on AFB smear microscopy owing to its simplicity, lower cost, and fast results.
The study period should also be considered. From 1994 to 2014, profound changes have occurred in transplantation medical care, which certainly impacted the risk of nephrotoxicity associated with TB treatment. However, to the best of our knowledge, this is the first study to assess the renal function of patients with TB after transplantation in a systematic fashion, adding new knowledge about this prevalent infection. Moreover, the understanding of the risk factors for non-recovery of baseline allograft function in these patients is an important step in the implementation of preventive actions.
In conclusion, TB after kidney transplantation was associated with a high incidence of AKI and, 3 months after the end of the treatment, GFR was significantly inferior to baseline. The severity of TB disease, the severity of AKI, and AR episodes were possible causes 
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